An observational study in Head and Neck Cancer, sponsored by Radboud University Medical Center. Status unknown at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-10-31.
Sponsored by Radboud University Medical Center · Observational
Various methods of FDG-PET signal segmentation will be validated by correlation of histopathologically measured tumor dimensions in lymph node dissection specimens of head-and-neck cancer patients.
2,344 studies on the registry are indexed under Head and Neck Neoplasms; 551 are open to participants now.
This study's planned enrollment of 15 is below the median of 100 across 441 observational studies indexed under Head and Neck Neoplasms.
Browse Head and Neck Neoplasms studies →Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
Exclusion Criteria:
Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
Other: CT-FDG/PET scan of the head-and-neck region
CT-FDG/PET scan of the head-and-neck region
How accurate are the various FDG-PET segmentation tools?
Time frame: Measurements are performed in conjunction with the clinical pathologist directly postoperatively.
This study is status unknown, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radboud University Medical Center